A novel upregulated LncRNA-AC026150.8 promotes chemo-resistance and predicts poor prognosis in acute myeloid leukemia

Background AML is a common hematological malignancy with poor prognosis, the pathogenesis is still unclear. lncRNA takes part in occurrence and development of AML. This research aims to explore new differentially expressed lncRNAs and their effects on AML. Methods Database-based bioinformatics analysis was performed to screen differentially expressed lncRNA in AML, real-time PCR was used to analyze gene expression. Kaplan-Meier survival analysis was performed to determine prognostic effect of AC026150.8 in AML. The cell drug resistance experiment was performed to test effect of AC026150.8 on chemo-resistance of AML cells. Catrapid online software and RNA pull-down, mass spectrometry, western-blot were used to predict and verify the combination of AC026150.8 and RNA splicing factors. Results AC026150.8 was upregulated in AML patients and related to poor prognosis. High leukocyte counts, FAB classification, MLL-AF9 expression and NPM1 mutations were associated with high AC026150.8 expression. Upregulated of AC026150.8 increased the drug resistance of AML cells. AC026150.8 could be combined with splicing factor PCBP1. Conclusions For the first time, our study found that the upregulated AC026150.8 in AML is related to poor prognosis, overexpression of AC026150.8 could increase drug resistance of AML cells, and confirmed its scaffolding effect in combination with splicing factors. It is necessary to further study AC026150.8 and its downstream target genes to clarify the mechanism of AC026150.8 in AML.

Automated summary

The upregulated AC026150.8 in AML is associated with poor prognosis, high leukocyte counts, FAB classification, MLL-AF9 expression, and NPM1 mutations. Upregulation of AC026150.8 increases drug resistance in AML cells and can interact with the splicing factor PCBP1. Further studies on AC026150.8 and its downstream target genes are needed to elucidate its mechanism in AML.